41 related articles for article (PubMed ID: 10840138)
1. Neuropeptide Y in brains of the Flinders Sensitive Line rat, a model of depression. Effects of electroconvulsive stimuli and d-amphetamine on peptide concentrations and locomotion.
Jiménez Vasquez PA; Salmi P; Ahlenius S; Mathé AA
Behav Brain Res; 2000 Jun; 111(1-2):115-23. PubMed ID: 10840138
[TBL] [Abstract][Full Text] [Related]
2. Neuropeptide S alters anxiety, but not depression-like behaviour in Flinders Sensitive Line rats: a genetic animal model of depression.
Wegener G; Finger BC; Elfving B; Keller K; Liebenberg N; Fischer CW; Singewald N; Slattery DA; Neumann ID; Mathé AA
Int J Neuropsychopharmacol; 2012 Apr; 15(3):375-87. PubMed ID: 21708052
[TBL] [Abstract][Full Text] [Related]
3. Repeated cannabidiol treatment affects neuroplasticity and endocannabinoid signaling in the prefrontal cortex of the Flinders Sensitive Line (FSL) rat model of depression.
Domingos LB; Müller HK; da Silva NR; Filiou MD; Nielsen AL; Guimarães FS; Wegener G; Joca S
Neuropharmacology; 2024 May; 248():109870. PubMed ID: 38401791
[TBL] [Abstract][Full Text] [Related]
4. Probiotics Affect One-Carbon Metabolites and Catecholamines in a Genetic Rat Model of Depression.
Tillmann S; Awwad HM; Eskelund AR; Treccani G; Geisel J; Wegener G; Obeid R
Mol Nutr Food Res; 2018 Apr; 62(7):e1701070. PubMed ID: 29453804
[TBL] [Abstract][Full Text] [Related]
5. Fear induced neuronal alterations in a genetic model of depression: an fMRI study on awake animals.
Huang W; Heffernan ME; Li Z; Zhang N; Overstreet DH; King JA
Neurosci Lett; 2011 Feb; 489(2):74-8. PubMed ID: 21134416
[TBL] [Abstract][Full Text] [Related]
6. Abnormal behaviors and microstructural changes in white matter of juvenile mice repeatedly exposed to amphetamine.
Yang HJ; Wang L; Cheng Q; Xu H
Schizophr Res Treatment; 2011; 2011():542896. PubMed ID: 22937267
[TBL] [Abstract][Full Text] [Related]
7. GALR2 and Y1R agonists intranasal infusion enhanced adult ventral hippocampal neurogenesis and antidepressant-like effects involving BDNF actions.
Alvarez-Contino JE; Díaz-Sánchez E; Mirchandani-Duque M; Sánchez-Pérez JA; Barbancho MA; López-Salas A; García-Casares N; Fuxe K; Borroto-Escuela DO; Narváez M
J Cell Physiol; 2023 Feb; 238(2):459-474. PubMed ID: 36599082
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder.
Mathé AA; Michaneck M; Berg E; Charney DS; Murrough JW
Int J Neuropsychopharmacol; 2020 Dec; 23(12):783-790. PubMed ID: 33009815
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between White Matter Integrity and Plasma Leptin Levels in Drug-Naïve and Medicated Patients With Major Depressive Disorder.
Amer AAA; Zhu Y; Wei S; Zhang R; Wang Y; Duan J; Jiang X; Tang Y; Wang F
Front Neurosci; 2019; 13():707. PubMed ID: 31354416
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptide Y in Alcohol Addiction and Affective Disorders.
Thorsell A; Mathé AA
Front Endocrinol (Lausanne); 2017; 8():178. PubMed ID: 28824541
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence.
Domin H; Szewczyk B; Pochwat B; Woźniak M; Śmiałowska M
Psychopharmacology (Berl); 2017 Feb; 234(4):631-645. PubMed ID: 27975125
[TBL] [Abstract][Full Text] [Related]
12. Relaxin' the brain: a case for targeting the nucleus incertus network and relaxin-3/RXFP3 system in neuropsychiatric disorders.
Kumar JR; Rajkumar R; Jayakody T; Marwari S; Hong JM; Ma S; Gundlach AL; Lai MKP; Dawe GS
Br J Pharmacol; 2017 May; 174(10):1061-1076. PubMed ID: 27597467
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid neuropeptide Y levels in major depression and reported childhood trauma.
Soleimani L; Oquendo MA; Sullivan GM; Mathé AA; Mann JJ
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539507
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Neuropeptide Y System in Stress-related Psychiatric Disorders.
Enman NM; Sabban EL; McGonigle P; Van Bockstaele EJ
Neurobiol Stress; 2015 Jan; 1():33-43. PubMed ID: 25506604
[TBL] [Abstract][Full Text] [Related]
15. Allele-specific programming of Npy and epigenetic effects of physical activity in a genetic model of depression.
Melas PA; Lennartsson A; Vakifahmetoglu-Norberg H; Wei Y; Åberg E; Werme M; Rogdaki M; Mannervik M; Wegener G; Brené S; Mathé AA; Lavebratt C
Transl Psychiatry; 2013 May; 3(5):e255. PubMed ID: 23652932
[TBL] [Abstract][Full Text] [Related]
16. Depression and antidepressants: molecular and cellular aspects.
Lanni C; Govoni S; Lucchelli A; Boselli C
Cell Mol Life Sci; 2009 Sep; 66(18):2985-3008. PubMed ID: 19521663
[TBL] [Abstract][Full Text] [Related]
17. Both acute and chronic buspirone treatments have different effects on regional 5-HT synthesis in Flinders Sensitive Line rats (a rat model of depression) than in control rats.
Nishi K; Kanemaru K; Hasegawa S; Watanabe A; Diksic M
Neurochem Int; 2009; 54(3-4):205-14. PubMed ID: 19084042
[TBL] [Abstract][Full Text] [Related]
18. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.
Nikisch G; Mathé AA; Czernik A; Thiele J; Bohner J; Eap CB; Agren H; Baumann P
Psychopharmacology (Berl); 2005 Oct; 181(4):751-60. PubMed ID: 15988572
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide expression in rats exposed to chronic mild stresses.
Sergeyev V; Fetissov S; Mathé AA; Jimenez PA; Bartfai T; Mortas P; Gaudet L; Moreau JL; Hökfelt T
Psychopharmacology (Berl); 2005 Mar; 178(2-3):115-24. PubMed ID: 15719227
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
